NEW YORK, NY, June 11, 2018 (GLOBE NEWSWIRE) -- Traders News Source, a leading independent equity research and corporate access
firm focused on small and mid-cap public companies is issuing a comprehensive report on ArQule Inc. (NASDAQ:
ARQL), a bio-pharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare
diseases.
The company announced that clinical data from the company-sponsored ARQ 531-101 Phase 1 dose escalation study in subjects with
relapsed or refractory hematologic malignancies would be presented on June 15, 2018, at the EHA Congress in Stockholm, Sweden.
Look at the company 2018 guidance, potential catalysts and pipeline READ MORE
Copy and paste to your browser may be required to view the report – https://tradersnewssource.com/arqule-inc/
The Company granted Basilea Pharmaceutica Ltd. an exclusive license to develop and commercialize derazantinib, its pan-FGFR
inhibitor, in all parts of the world except the People’s Republic of China, Hong Kong, Macau and Taiwan,
where the Company has licensed rights to Sinovant Sciences, Ltd., a subsidiary of Roivant Sciences Ltd. Terms of the
transaction include a $10 million upfront payment, an additional $326 million in regulatory and commercial milestones, and
royalties on net sales ranging from single to double digits; Basilea will be responsible for all costs and expenses of development,
manufacture, and commercialization in its territory.
Recent highlights and near-term potential catalysts here READ MORE
Copy and paste to your browser may be required to view the report – https://tradersnewssource.com/arqule-inc/
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities
mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in
full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any
agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information,
visit https://www.tradersnewssource.com.
To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
CONTACT: Traders News Source editor@tradersnewssource.com
